In a recent study, researchers found that people taking the new anti-COVID drug molnupiravir eliminated SARS-CoV-2 virus by day three of starting therapy, while many participants who received placebo took up to five days and in some cases longer to achieve this.
Molnupiravir is an oral antiviral prodrug with broad activity against coronaviruses, including SARS-CoV-2 and its variants of concern.
The study confirmed the superiority of molnupiravir in people with mild/moderate COVID-19 at risk of severe disease, provided they started therapy within five days of symptom onset.
The drug has been granted an emergency use authorisation by the by the US Food and Drug Administration (FDA) and is also authorized for use in the UK, Australia, and Japan and 12 other jurisdictions.
In the study, PCR testing was used to determine SARS-CoV-2 RNA viral loads.
The team demonstrated that on day three of treatment, infectious SARS-CoV-2 was detected in zero of 92 participants with the infectious virus at baseline who received molnupiravir.
On Day 5, virus was detected in 0.0% in the molnupiravir group compared with 2.2% in the placebo group.
The findings showed that a 5-day treatment course of twice-daily 800 mg molnupiravir results in a more rapid decline in viral RNA and faster elimination of the infectious virus.
This study provides additional evidence that molnupiravir helps those infected clear SARS-CoV-2 faster than placebo, and that molnupiravir can lower the risk of progression to serious illness.
Molnupiravir is now in the process of being submitted to global regulatory authorities for emergency use authorization or approval in other countries and jurisdictions, such as the European Medicines Agency (EMA) and is being studied in a Phase three trial.
If you care about Covid, please read studies about old drug that could save your life from COVID-19, and findings of a new way to prevent many COVID-19 variants.
For more information about Covid, please see recent studies about why some people are less naturally resistant to COVID-19, and results showing this drug combo may help cure COVID-19.
The research is published in NEJM and was conducted by Dr. Julie Strizki et al. from the pharmaceutical company MSD.
Copyright © 2022 Knowridge Science Report. All rights reserved.
